Houston Alzheimer Disease Study

Investigator: Joseph Masdeu, MD

Study Coordinator: Andrea Franco Pando

Status: Enrolling

ClinicalTrials.gov Number: NCT99999999

Phone: 713.441.1150

Protocol Number: PRO00025999

Description

The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abilities. Various types of brain imaging (Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET)) will tell us whether the patient have any of the abnormal proteins, amyloid and tau, that build up in the brain of people with Alzheimer’s disease. Body fluid samples (Blood and Cerebrospinal fluid (CSF)) will be extensively studied, to detect abnormalities that doctors are yet not aware of. We will measure the memory and other thinking abilities, which may be altered by the brain changes that occur in Alzheimer’s disease and similar diseases. We aim to provide data to set up a system to share the data we collect so that leading researchers working in this field can accelerate the discovery of new treatments.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials